Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Corbus Pharmaceuticals Holdings Inc CRBP

Healthcare Biotechnology
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.


NDAQ:CRBP - Post by User

Corbus Pharmaceuticals Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(140)
•••
Post by INVESTigator1on May 05, 2021 12:12pm
98 Views
Post# 33132511

1933 Industries Preferred Supplier Las Vegas & Nevada

1933 Industries Preferred Supplier Las Vegas & NevadaIf anyone is looking for a cannabis stock that will easily quadruple and more this year – TGIFF (US) TGIF (CN) is the ticker with the AMA and Canna Hemp (CBD) high quality products, It has huge integration with Nevada dispensaries and Vegas is coming back big in just months... Now undervalued <8cents...
1,170 posts
10.2k followers
812 following
Alternative Medicine Assoc
Award Winners
“The OG’s”
1st Licensed Cultivator in Las Vegas
Nothing for Sale | NRS453A Compliant
For Use by Adults 21 Years and Older Only
amanev.com Instagram AMANev702
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities